SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?


To: D.Right who wrote (1124)2/18/1998 8:33:00 PM
From: arnie h  Read Replies (3) | Respond to of 2173
 
D. et al- Wasn't able to get the answer to my question of whether 75% applied to the 43 type 2 patients who had stable dosing. Apparently, the data isn't in a form that allows ready analysis on that, or that question just hasn't come up.

I would note the original release which Henry just repeated stated the 75% figure for both type 1 and type 2. Any thoughts on the significance of that?

Regards.